I've created an army of biotech skeptics on Twitter. #proud— Adam Feuerstein (@adamfeuerstein) August 28, 2013I meant what I tweeted Wednesday night. Sincerely. Instead of "skeptics" I could have said "independent thinkers." The high level of analysis and insight into biotech stocks being discussed on Twitter these days -- MannKind ( MNKD), Arena Pharma ( ARNA), Pharmacyclics ( PCYC), Celgene ( CELG), to name a few -- is surpassing anything you'll hear or read from the sell side and in many instances rivals buyside analysis. For a long time, Twitter was mainly the place for traders to keep tabs on hot stocks. Today, I'm seeing tweets from people expertly versed in deep fundamental analysis of clinical data and financial information. "Bio-Twitter" is maturing into an absolutely essentially investment resource.